共查询到20条相似文献,搜索用时 281 毫秒
1.
Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China
下载免费PDF全文
![点击此处可从《Helicobacter》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Yong Xie Zhenyu Zhang Junbo Hong Wenzhong Liu Hong Lu Yiqi Du Weihong Wang Jianming Xu Xuehong Wang Lijuan Huo Guiying Zhang Chunhui Lan Xiaoyan Li Yanqing Li Hong Wang Guoxin Zhang Yin Zhu Xu Shu Ye Chen Jiangbin Wang Nonghua Lu the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori 《Helicobacter》2018,23(5)
Background
The efficacy of Helicobacter pylori (H. pylori) eradication has steadily declined, primarily because of antibiotic resistance. This study aimed to evaluate the efficacy and safety of furazolidone eradication therapies as initial treatments for H. pylori infection.Methods
A national, multicenter, open‐label, randomized controlled trial was performed at 16 sites across 13 provinces in China to evaluate the efficacy and safety of furazolidone‐containing therapies for H. pylori infection. Treatment naïve patients were randomly assigned to: esomeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, and furazolidone 100 mg twice daily for 10 and 7 days (FAB 10 and FAB 7; the same therapy without bismuth (FA 10 and FA 7). The primary and secondary outcomes were the eradication rate and regimen safety, respectively. Treatment success was assessed by the 13C urea breath test at least 4 weeks after treatment completion.Results
Overall, according to intention‐to‐treat (ITT) analysis, the eradication rates for FAB 10 and FAB 7 were 86.6% (95% confidence interval [CI], 79.9%‐93.2%) and 83.6% (95% CI, 76.3%‐90.9%) and for FA 10 and FA 7 were 82.4% (95% CI, 74.9%‐89.8%) and 77.6% (95% CI, 69.4%‐85.8%), respectively. According to per‐protocol analysis, the overall eradication rates for FAB 10 and FAB 7 were 94.7% (95% CI, 90.3%‐99.1%) and 90.8% (95% CI, 85.1%‐96.5%) and for FA 10 and FA 7 were 90.6% (95% CI, 84.9%‐96.3%) and 85.1% (95% CI, 78.2%‐92.1%), respectively. The overall prevalence of side effects was 8.1%.Conclusions
Furazolidone‐containing therapies, particularly the tested 10‐day quadruple therapy, exhibited satisfactory efficacy and safety. This 10‐day quadruple therapy represents a promising initial treatment strategy for Chinese patients. 相似文献2.
3.
4.
5.
6.
7.
8.
9.
Daisuke Asaoka Akihito Nagahara Takeshi Matsuhisa Shin‐ichi Takahashi Kengo Tokunaga Takashi Kawai Kohei Kawakami Hidekazu Suzuki Masayuki Suzuki Toshihiro Nishizawa Naoto Kurihara Masayoshi Ito Hitoshi Sasaki Fumio Omata Shigeaki Mizuno Akira Torii Toshifumi Ohkusa Tetsuya Mine Nobuhiro Sakaki 《Helicobacter》2013,18(6):468-472
10.
11.
12.
13.
Brief report: Lactobacillus bulgaricus GLB44 (Proviotic™) plus esomeprazole for Helicobacter pylori eradication: A pilot study
下载免费PDF全文
![点击此处可从《Helicobacter》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Background
Recent studies of Lactobacillus delbrueckii subsp. bulgaricus GLB44 plus a proton‐pump inhibitor (PPI) reported cures of more than 90% of patients with active Helicobacter pylori infections.Aim
To confirm the high H. pylori cure rates reported previously.Method
A pilot study was done in healthy H. pylori‐infected volunteers using 3‐gram sachet (3 billion cells) of L. delbrueckii GLB44 plus 22.3 mg of esomeprazole b.i.d., for 14 days. The result was determined by urea breath testing 4 weeks after therapy. Stopping rules required for ending enrollment if less than 3 of the first 10 subjects were cured.Results
Nine subjects were entered and because all failed to achieve negative urea breath test, the stopping rule required the study to end.Conclusion
We were unable to confirm reports of achieving a high H. pylori cure rate with L. delbrueckii GLB44 plus a PPI. 相似文献14.
15.
16.
17.
New bismuth‐containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice
下载免费PDF全文
![点击此处可从《Helicobacter》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Antonio Tursi Francesco Di Mario Marilisa Franceschi Rudi De Bastiani Walter Elisei Gianluca Baldassarre Antonio Ferronato Simone Grillo Stefano Landi Maria Zamparella Manuela De Polo Laura Boscariolo Marcello Picchio 《Helicobacter》2017,22(3)
18.
Marco Romano Antonietta Gerarda Gravina Gerardo Nardone Alessandro Federico Marcello Dallio Marco Martorano Caterina Mucherino Alessandra Romiti Luciana Avallone Lucia Granata Katerina Priadko Debora Compare Concetta Tuccillo Maria Raffaella Romito Dolores Sgambato Agnese Miranda Lorenzo Romano Carmelina Loguercio Franco Bazzoli Rocco Maurizio Zagari 《Helicobacter》2020,25(4)
19.
Celia J. Vogel Marjon A. Smit Gianluca Maddalo Patricia A. Possik Rolf W. Sparidans Sjoerd H. van der Burg Els M. Verdegaal Albert J. R. Heck Ahmed A. Samatar Jos H. Beijnen A. F. Maarten Altelaar Daniel S. Peeper 《Pigment cell & melanoma research》2015,28(3):307-317
No effective targeted therapy is currently available for NRAS mutant melanoma. Experimental MEK inhibition is rather toxic and has only limited efficacy in clinical trials. At least in part, this is caused by the emergence of drug resistance, which is commonly seen for single agent treatment and shortens clinical responses. Therefore, there is a dire need to identify effective companion drug targets for NRAS mutant melanoma. Here, we show that at concentrations where single drugs had little effect, ROCK inhibitors GSK269962A or Fasudil, in combination with either MEK inhibitor GSK1120212 (Trametinib) or ERK inhibitor SCH772984 cooperatively caused proliferation inhibition and cell death in vitro. Simultaneous inhibition of MEK and ROCK caused induction of BimEL, PARP, and Puma, and hence apoptosis. In vivo, MEK and ROCK inhibition suppressed growth of established tumors. Our findings warrant clinical investigation of the effectiveness of combinatorial targeting of MAPK/ERK and ROCK in NRAS mutant melanoma. 相似文献
20.
Bacteriophages and bacteriophage‐derived endolysins as potential therapeutics to combat Gram‐positive spore forming bacteria
下载免费PDF全文
![点击此处可从《Journal of applied microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Since their discovery in 1915, bacteriophages have been routinely used within Eastern Europe to treat a variety of bacterial infections. Although initially ignored by the West due to the success of antibiotics, increasing levels and diversity of antibiotic resistance is driving a renaissance for bacteriophage‐derived therapy, which is in part due to the highly specific nature of bacteriophages as well as their relative abundance. This review focuses on the bacteriophages and derived lysins of relevant Gram‐positive spore formers within the Bacillus cereus group and Clostridium genus that could have applications within the medical, food and environmental sectors. 相似文献